-
Personalized mRNA vaccine cuts melanoma relapse risk by 42%
An mRNA therapy designed from each patient's own tumor cut the risk of relapse or death by 42% in people who had surgery for melanoma. It is the first phase 3 trial to show this.
Good news about mRNA
Every good news story tagged "mRNA".